Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Somnomed Limited ( (AU:SOM) ) has provided an update.
SomnoMed Limited announced that its half-year financial results for FY25 and an investor presentation will be released on February 28, 2025. The release will be followed by a webinar hosted by the management to discuss the results and engage in a Q&A session, highlighting the company’s proactive approach in maintaining transparency with its investors.
More about Somnomed Limited
SomnoMed is a public company specializing in treatment solutions for sleep-related breathing disorders such as obstructive sleep apnea, snoring, and bruxism. The company is known for its SomnoDent® oral appliance therapy, which is based on extensive clinical research and is used by over 940,000 patients in more than 20 countries.
YTD Price Performance: 143.03%
Average Trading Volume: 4,568
Technical Sentiment Consensus Rating: Hold
Current Market Cap: $87.86M
See more insights into SOM stock on TipRanks’ Stock Analysis page.
